Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-09-02
2008-09-02
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S375000, C514S534000, C514S423000
Reexamination Certificate
active
11464537
ABSTRACT:
The present invention relates to the compounds of formula (I):in which A is a group of formula (a) or (b)in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1represents a hydrogen atom or a (C1-C4)alkyl group, a —CO(C1-C4)alkyl group, a phenyl-(C1-C4)alkyl group or a —COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C1-C4)alkoxy group; R2is a hydrogen atom or an —SO2(C1-C4)alkyl group, an —SO2phenyl-(C1-C4)alkyl group or an —SO2phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C1-C4)alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R3represents a hydrogen or halogen atom, a (C1-C6)alkyl group, a (C1-C4)alkoxy group, a —COO(C1-C4)alkyl group, a —CO(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl groups, —NO2, —CN, —CONR4R5, —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R4and R5represent, independently, a hydrogen atom, a phenyl, a (C1-C4)alkyl group or a phenyl-(C1-C4)alkyl group or R4and R5with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.
REFERENCES:
patent: 4004028 (1977-01-01), Kaiser
patent: 5096908 (1992-03-01), Gidda et al.
patent: 5158956 (1992-10-01), Gidda et al.
patent: 5258379 (1993-11-01), Gidda et al.
patent: 5340838 (1994-08-01), Gidda et al.
patent: 5457120 (1995-10-01), Gidda et al.
patent: 5532244 (1996-07-01), Wong et al.
patent: 5532250 (1996-07-01), Wong et al.
patent: 5532264 (1996-07-01), Wong et al.
patent: 5532268 (1996-07-01), Wong et al.
patent: 5538992 (1996-07-01), Wong et al.
patent: 5552429 (1996-09-01), Wong et al.
patent: 5576352 (1996-11-01), Gidda et al.
patent: 5594025 (1997-01-01), Gidda et al.
patent: 5594034 (1997-01-01), Gidda et al.
patent: 5776969 (1998-07-01), James
patent: 5958429 (1999-09-01), Wong
patent: 6169105 (2001-01-01), Wong et al.
patent: 6730792 (2004-05-01), Evers et al.
patent: 6890955 (2005-05-01), Hadri et al.
patent: 2002/0019440 (2002-02-01), Philippe et al.
patent: 2003/0191156 (2003-10-01), Evers et al.
patent: 2004/0053916 (2004-03-01), Bovy et al.
patent: 2004/0242633 (2004-12-01), Evers et al.
patent: 2005/0176731 (2005-08-01), Bovy et al.
patent: 2005/0239836 (2005-10-01), John et al.
patent: 2006/0100283 (2006-05-01), Bovy et al.
patent: 0345056 (1989-12-01), None
patent: 642787 (1995-03-01), None
patent: 2000086603 (2000-03-01), None
patent: WO 02/00622 (2002-01-01), None
patent: WO 94/11386 (1994-05-01), None
patent: WO 97/31629 (1997-09-01), None
patent: WO 9831357 (1998-07-01), None
patent: WO 99/65895 (1999-12-01), None
patent: WO 00/38685 (2000-07-01), None
patent: WO 00/40561 (2000-07-01), None
patent: WO 02/058697 (2002-08-01), None
patent: WO 03/099772 (2003-12-01), None
patent: WO 2004/006849 (2004-01-01), None
patent: WO 2004/019932 (2004-03-01), None
patent: WO 2004/076413 (2004-09-01), None
Abitayeh, et al. “New tocolytic agents”, Eur. Clinics Obstet. Gynaecol. (2005) 1: 29-35.
Bardou, et al. “Functional, biochemical and molecular biological evidence for a possible B3-adrenoceptor in human near-term myometrium”, British Journal of Pharmacology (2000) 130: 1960-1966.
Hoffstedt, et al. “Determination of beta 3-adrenoceptor mediated lipolysis in human fat cells”, Obesity Research (1995) 3: 447-457. Abstract only.
Weyer, et al. “Development of beta3-adrenoceptor agonists for the treatment of obesity and diabetes—an update”, Diabetes & Metabolism (Paris) (1999) 25: 11-21.
Collins, et al. “Strain-Specific Response to β3-Adrenergic Receptor Agonist Treatment of Diet-Induced Obesity in Mice”, Endocrinology, vol. 138(1), pp. 405-413 (1997).
Sum, et al. “Prodrugs of CL316243: A Selective β3-Adrenergic Receptor Agonist for Treating Obesity and Diabetes”, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1921-1926 (1999).
Sasaki, et al. “Anti-Obesity Effects of Selective Agonists to the β3-Adrenergic Receptor in Dogs. II. Recruitment of Thermogenic Brown Adipocytes and Reduction of Adiposity after Chronic Treatment with a β3-Adrenergic Agonist”, Japanese Society of Veterinary Science, vol. 60(4), pp. 465-469 (1998).
Rathi, et al. “Functional and Molecular Characterization of Beta Andreoceptors in the Internal Anal Sphincter”, Journal of Pharmacology and Experimental Therapeutics, vol. 305(2), pp. 615-624 (2003).
ClinicalTrials.gov, “A Study to Investigate GW427353 In Subjects with Irritable Bowel Syndrome (IBS)”, NCT00394186 (2008).
Dennedy, et al. “β2 and β3-Adrenoreceptor agonists: Human myometrial selectivity and effects on umbilical artery tone”, Am. J. Obstet. Gynecol., vol. 187(33), pp. 641-647 (2002).
Croci, et al. “In Vitro and in Vivo Pharmacological Characterization of Ethyl-4-{trans-4-[((2S)-2-hydroxy-3-{4-hydroxy-3[(methylsulfonyl)amino]-phenoxy}propyl) Amino]cyclohexyl}benzoate Hydrochloride (SAR150640), a New Potent and Selective Human β3-Adrenoceptor Agonist for the Treatment of Preterm Labor”, J. Pharm. Exp. Ther., vol. 321, 2007.
Fletcher, et al., “Beta-3 Adrenergic Receptor Agonists Cause an Increase in Gastrointestinal Transit Time in Wild-type Mice, But Not in Mice Lacking the Beta-3 Adrenergic Receptor”, Journal of Pharmacology and Experimental Therapeutics, vol. 287, pp. 720-724 (1998).
Martin, C., et al., Beta3-adrenoceptor agonists, BRL 37344 and SR 58611A, do not induce relaxation of human, sheep and guinea-pig airway smooth muscle in vitro, Eur Respir J., 1994, 7, 1610-1615.
Bovy Philippe R.
Cecchi Roberto
Courtemanche Gilles
Croci Tiziano
Oliva Ambrogio
Anderson Rebecca L
Barker Michael P
Lin Jiang
Sanofi-Aventis
LandOfFree
Cyclohexyl(alkyl)propanolamines, preparation method and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclohexyl(alkyl)propanolamines, preparation method and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclohexyl(alkyl)propanolamines, preparation method and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3914635